...: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate marker of OS in pancreatic cancer chemotherapy focusing on FOLFIRINOX...

... good antitumor and survival prolongation effects. Post-progression survival (PPS) has been reported to be a great contributor in the treatment with tyrosine kinase inhibitors for unresectable HCC. This study aimed to clarify the significance of progression-free survival (PFS) or PPS of Atez/Bev...

... survival (PFS1) was defined as the period from the start of nivolumab treatment to death or first disease progression, and second progression-free survival (PFS2) was defined as the time from the first administration of nivolumab to death or second progression. The OS, PFS1, and PFS2 were compared using...

... lung cancer (NSCLC), the impact of first-line treatment on overall survival (OS) may be influenced by subsequent therapies. Thus, using patient-level data, we assessed the relationships of progression-free survival (PFS) and post-progression survival (PPS) with OS among patients with high-programmed...

... regorafenib at 160 mg/day during the first 3 weeks of each 4-week cycle were divided into subgroups based on whether they developed HFSR between May 2013 and October 2015. Estimates of overall survival and progression-free survival were calculated using the Kaplan-Meier method. Results: Ninety-seven patients...

... received the same dose of eribulin as that used in the EMBRACE trial: 1.4 mg/m 2 on days 1 and 8 every 21 days. Results: In a total of 53 patients, 32% obtained a partial response, 11% a stable disease, and 43% a clinical benefit (CB). After a median follow-up of 36 months, median progression-free survival...

... and safety of eribulin in a real-world population of metastatic breast cancer (MBC) patients and to identify possible predictive factors of progression-free survival (PFS) and objective response. Methods: We retrospectively analyzed 71 eribulin-treated MBC patients. Best response rate, PFS, and adverse...

... and advanced stage [ 7,8,9,10,11,12,13 ]. Endometrial cancer Stage I/II endometrial cancer Hysterectomy Progression-free survival Overall survival Adverse effect Table 2 Multivariate analysis for PFS and OS in the patients treated with TAH (n = 46) and mRH (n = 201) Table 4...

... Evaluation Criteria in Solid Tumors, progression-free survival (PFS), and overall survival (OS). Results: Seventy-nine placebo-treated patients from VEG105192/NCT00334282 who experienced disease progression and one pazopanib-treated patient (an exemption) were enrolled. Forty-one patients (51%) were...

...Lisa N. Abaid; Bram H. Goldstein; John P. Micha; Mark A. Rettenmaier; John V. Brown, III; Maurie Markman Objectives: Previously reported studies have suggested that maintenance therapy in the treatment of ovarian cancer may provide progression-free survival (PFS) benefits, although they have...

...Alberto Sobrero; Stephen Ackland; Stephen Clarke; Ramón Perez-Carrión; Silvia Chiara; John Gapski; Paul Mainwaring; Bernd Langer; Scott Young Background: Bevacizumab (Avastin®) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan...

... immunocytochemistry. Tumor specimens were obtained upon primary tumor nephrectomy. In all patients, progression-free survival time following nephrectomy was evaluated and correlated statistically with the staining results. Progression-free survival of patients with no or very few ( < 1%) P-glycoprotein-positive...